PACB

#3024
Pacific Biosciences of California, Inc. - Common Stock
1.3 2 USD
-0.03%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.30
1.34
Intervallo Annuale
1.07
2.73
Variazione giornaliera
-2.94%
Variazione Mensile
-7.69%
Variazione di 6 mesi
-17.50%
Variazione Annuale
+1.54%
Chiusura Precedente
1.3 6
Open
1.3 3
Minimo
1.3 0
Massimo
1.3 4
Volume
650
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, 27 April 2021

Full document

Business Context and Reporting Period

Company: Pacific Biosciences of California, Inc. (PACB)
Filing Type: Form 8-K (Current Report)
Date of Report: April 27, 2021
Reporting Period: Specific event date (April 27, 2021)

This filing reports a corporate governance event regarding the nomination of a new director for the 2021 Annual Meeting of Stockholders.

Key Financial Metrics

This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is limited to a disclosure of a board nomination event.

Material Changes

Board of Directors Composition:

  • New Nominee: The Board has nominated Dr. Hannah A. Valantine to stand for election as a Class II director.
  • Departing Director: Dr. Michael Hunkapiller, currently a Class II director, is not standing for re-election. He will continue to serve until the expiration of his current term at the 2021 Annual Meeting.

Background of New Nominee:

  • Professor of Medicine (Cardiovascular) at Stanford University Medical Center since 1987.
  • Former Chief Officer for Scientific Workforce Diversity at the National Institutes of Health (2014–2020).
  • Founder and Principal of HAV LLC, a diversity, equity, and inclusion consulting firm (founded January 2021).

Guidance, Outlook, and Risks

Forward-Looking Statements: The filing contains forward-looking statements regarding the 2021 Annual Meeting. The Company cautions that actual results may differ materially from expectations due to various risks and uncertainties. The Company disclaims any obligation to update these statements.

Related Party Transactions: The filing explicitly states there are no family relationships between Dr. Valantine and any director or executive officer, and no reportable related party transactions exist.

Investor Action: Stockholders are advised to read the full proxy statement for the 2021 Annual Meeting before voting, as it contains detailed information not included in this 8-K.

Key Facts for Investor Verification

  • Verify the final election results for Dr. Hannah A. Valantine in the proxy statement or subsequent filings.
  • Review the full proxy statement for the 2021 Annual Meeting for comprehensive biographical details and voting procedures.
  • Confirm the exact date of the 2021 Annual Meeting to determine when Dr. Hunkapiller's term officially expires.
  • Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.

Notizie